E-drug: Appropriate use indicators for coronary heart disease
----------------------------------------------------------
Dear Members:
We are performing a proposal research to audit appropriate use of
Angiotensin-coverting enzyme inhibitors and thrombolytic therapy in
Coronary Heart Disease, in the main hospital in our city. To define
appropriate use of those drugs, we will use the WHO general definition.
Does anyone know some research about this issue? May anyone suggest
possible criteria/indicators?
Many thanks anticipated
Arturo Marti-Carvajal
Universidad de Carabobo
Venezuela
amarti@thor.uc.edu.ve
[Note from moderator: Arturo has also posted this question to
evidence-based-health@mailbase.ac.uk; procor@usa.healthnet.org Kirsten Myhr]
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.